Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1982;8(3):293-9.
doi: 10.1007/BF00254053.

Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer

J M Gilbert, K Hellmann, M Evans, P G Cassell, B Stoodley, H Ellis, C Wastell
Clinical Trial

Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer

J M Gilbert et al. Cancer Chemother Pharmacol. 1982.

Abstract

One hundred and seventy six patients (81 controls, 95 receiving treatment) have entered a prospective randomized trial of long-term oral adjuvant razoxane (ICRF-159) following removal of a colorectal cancer. The median follow-up is 34 months. The treated patients in Dukes' groups B and C have a significantly longer disease-free interval than the control patients (P = 0.01 'as randomized' and P = 0.004 'as treated'). The differences in survival for Dukes' groups B and C are not significant, although follow-up is short. In Dukes' groups B and C, however, 24 of 56 of the patients in the control group have died (43%), as against only 17 of 64 in the treatment group (27%). The treatment produces very few side-effects, is well tolerated by patients, and is taken orally.

PubMed Disclaimer

References

    1. Proc R Soc Med. 1944 Feb;37(4):131-44 - PubMed
    1. Acta Chir Scand Suppl. 1973;438:1-86 - PubMed
    1. Cancer Clin Trials. 1978 Winter;1(4):273-87 - PubMed
    1. Cancer Chemother Rep. 1975 Jul-Aug;59(4):761-3 - PubMed
    1. Br J Cancer. 1977 Jan;35(1):1-39 - PubMed

Publication types